• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Pharmacovigilance Analytics

Your best resource for PV analytics news, content and innovation!

  • Home
  • Pharmacovigilance Analytics
    • Sources of data
    • Methods and tools
  • Signal Detection and Management in Pharmacovigilance
  • News
  • Opinion
  • About
  • Glossary

Drug Master File – DMF

January 5, 2024 by Jose Rossello

A Drug Master File (DMF) is a submission to the Food and Drug Administration (FDA) in the United States that provides detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, or storing of one or more human drugs. Essentially, it’s a document that allows the FDA to review this information in support of a third party’s submission, like a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA), without revealing the information to that third party.

Key Aspects of a Drug Master File:

  1. Content: A DMF contains comprehensive information about the components, materials, and manufacturing processes of a drug but does not include the actual drug’s efficacy and safety data.
  2. Types of DMFs: There are several types, including:
    • Type I: Manufacturing Site, Facilities, Operating Procedures, and Personnel (no longer used).
    • Type II: Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation, or Drug Product.
    • Type III: Packaging Material.
    • Type IV: Excipient, Colorant, Flavor, Essence, or Material Used in Their Preparation.
    • Type V: FDA Accepted Reference Information.
  3. Confidentiality: The information in a DMF is proprietary and confidential. The FDA does not disclose it to third parties unless authorized by the DMF holder.
  4. Purpose for Drug Sponsors: Drug sponsors reference a DMF in their drug application to the FDA (e.g., NDA, ANDA) to show that certain components of their product meet regulatory guidelines for quality and safety. This allows them to use the data without having access to the proprietary details.
  5. Purpose for DMF Holders: For manufacturers of drug components, it’s a way to share detailed information with the FDA without disclosing proprietary information directly to multiple customers.
  6. Review and Approval: The FDA does not approve or disapprove DMFs, but they review the information as part of the review of an NDA, ANDA, or other related submissions.
  7. Maintenance and Updates: DMF holders are responsible for updating the DMF with any significant changes in the product, manufacturing process, or specifications.

Importance in Drug Development and Regulation:

  • Protecting Proprietary Information: DMFs allow suppliers to protect their proprietary information while providing necessary data for regulatory approval of a drug.
  • Facilitating Regulatory Approval: They facilitate the regulatory approval process for drug products by allowing drug sponsors to reference quality data about components without having to include all the details in their application.
  • Global Impact: While specific to the FDA in the United States, the concept of a DMF or similar documentation exists in other regulatory environments worldwide, playing a crucial role in global drug development and supply chains.

In summary, a Drug Master File is a critical regulatory document that provides detailed and confidential information about drug components and manufacturing processes to the FDA, aiding in the approval process of new drugs and ensuring the quality and safety of pharmaceutical products.

Related Terms:
  • Term: Excipient

Primary Sidebar

Subscribe in a reader

Search Website

Uses of Generative AI in Pharmacovigilance

Featured News / Posts

Signal Analytics Technology in Pharmacovigilance

Signal Analytics Technology in Pharmacovigilance: Enhancing Drug Safety Monitoring

Pharmacovigilance plays a crucial role in ensuring public safety by monitoring, … [Read More...] about Signal Analytics Technology in Pharmacovigilance: Enhancing Drug Safety Monitoring

8 Common FDA Applications for Drugs & Biologics

The U.S. Food and Drug Administration (FDA) has several types of applications … [Read More...] about 8 Common FDA Applications for Drugs & Biologics

Key IND Enabling Studies: Navigating Preclinical Development Regulations

Investigational New Drug (IND) applications represent a critical stage in the … [Read More...] about Key IND Enabling Studies: Navigating Preclinical Development Regulations

Pharmacokinetics and Pharmacodynamics (PKPD): Fundamentals in Drug Development and Therapeutic Effectiveness

Pharmacokinetics and pharmacodynamics are two fundamental pillars in the field … [Read More...] about Pharmacokinetics and Pharmacodynamics (PKPD): Fundamentals in Drug Development and Therapeutic Effectiveness

Current Regulations Regarding Reference Safety Information (RSI): Key Aspects and Updates

Regulatory authorities in the pharmaceutical industry have established standards … [Read More...] about Current Regulations Regarding Reference Safety Information (RSI): Key Aspects and Updates

Methods of Statistical Signal Detection in Patient Safety and Pharmacovigilance: Key Techniques and Approaches

In the realm of patient safety and pharmacovigilance, statistical signal … [Read More...] about Methods of Statistical Signal Detection in Patient Safety and Pharmacovigilance: Key Techniques and Approaches

Pharmacovigilance Signal Detection Software: Enhancing Drug Safety and Monitoring

Pharmacovigilance signal detection software plays a crucial role in … [Read More...] about Pharmacovigilance Signal Detection Software: Enhancing Drug Safety and Monitoring

What is a PBRER? Understanding Periodic Benefit-Risk Evaluation Reports

A Periodic Benefit-Risk Evaluation Report (PBRER) serves as a structured … [Read More...] about What is a PBRER? Understanding Periodic Benefit-Risk Evaluation Reports

Drug Safety vs Pharmacovigilance: Exploring Conceptual Differences

Drug safety and pharmacovigilance are crucial aspects of public … [Read More...] about Drug Safety vs Pharmacovigilance: Exploring Conceptual Differences

Which Sections of a DSUR Must Present Safety and Pharmacovigilance Quantitative Data: Key Components Explained

he Development Safety Update Report (DSUR) is a crucial document that serves as … [Read More...] about Which Sections of a DSUR Must Present Safety and Pharmacovigilance Quantitative Data: Key Components Explained

  • What is a DSUR (Development Safety Update Report)? An Essential Guide for Clinical Research
  • What is a BLA (Biologics License Application)? Essential Guide for Professionals
  • What is a PADER? – Periodic Adverse Drug Experience Report Explained

RSS ICH News

  • An error has occurred, which probably means the feed is down. Try again later.

RSS From Nature journal

  • PET-based tracking of CAR T cells and viral gene transfer using a cell surface reporter that binds to lanthanide complexes
  • Analysis and risk assessment of nitrosamines in sartans using GC-MS and Monte Carlo simulation
  • Medication safety analysis of elderly inpatients based on improved functional resonance analysis method (FRAM): a mixed methods study
  • Unraveling the mechanisms of irAEs in endometrial cancer immunotherapy: insights from FAERS and scRNA-seq data
  • Artemisinin derivatives differently affect cell death of lung cancer subtypes by regulating GPX4 in patient-derived tissue cultures

Copyright © 2025 · News Pro on Genesis Framework · WordPress · Log in